FR23C1036I1 - ANTIBODIES THAT BIND TO IL-23 - Google Patents

ANTIBODIES THAT BIND TO IL-23

Info

Publication number: FR23C1036I1
Authority: FR; France
Prior art keywords: antibodies; bind
Prior art date: 2013-03-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR23C1036C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Eli Lilly and Co

Original Assignee

Eli Lilly and Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-08

Filing date

2023-10-13

Publication date

2023-12-08

2023-10-13 Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co

2023-12-08 Publication of FR23C1036I1 publication Critical patent/FR23C1036I1/en

Status Active legal-status Critical Current

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

FR23C1036C 2013-03-08 2023-10-13 ANTIBODIES THAT BIND TO IL-23 Active FR23C1036I1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361774732P	2013-03-08	2013-03-08
PCT/US2014/020064 WO2014137962A1 (en)	2013-03-08	2014-03-04	Antibodies that bind il-23

Publications (1)

Publication Number	Publication Date
FR23C1036I1 true FR23C1036I1 (en)	2023-12-08

Family

ID=51488096

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR23C1036C Active FR23C1036I1 (en)	2013-03-08	2023-10-13	ANTIBODIES THAT BIND TO IL-23

Country Status (40)

Country	Link
US (3)	US9023358B2 (en)
EP (3)	EP3789037A1 (en)
JP (1)	JP6096938B2 (en)
KR (2)	KR20170103037A (en)
CN (1)	CN105307681B (en)
AP (1)	AP2015008708A0 (en)
AR (1)	AR094877A1 (en)
AU (1)	AU2014226094B2 (en)
BR (1)	BR112015019611B1 (en)
CA (1)	CA2901462C (en)
CL (1)	CL2015002388A1 (en)
CY (1)	CY1123589T1 (en)
DK (1)	DK2964258T3 (en)
EA (1)	EA031524B1 (en)
EC (1)	ECSP15038626A (en)
ES (1)	ES2822662T3 (en)
FI (1)	FIC20230030I1 (en)
FR (1)	FR23C1036I1 (en)
HK (1)	HK1212252A1 (en)
HR (1)	HRP20201633T1 (en)
HU (2)	HUE051357T2 (en)
IL (2)	IL240731B (en)
JO (1)	JOP20140049B1 (en)
LT (1)	LT2964258T (en)
MA (1)	MA38382A1 (en)
MX (1)	MX370396B (en)
MY (1)	MY171226A (en)
NL (1)	NL301247I2 (en)
PE (1)	PE20151529A1 (en)
PH (1)	PH12015501994A1 (en)
PL (1)	PL2964258T3 (en)
PT (1)	PT2964258T (en)
RS (1)	RS60928B1 (en)
SG (1)	SG11201507176VA (en)
SI (1)	SI2964258T1 (en)
TN (1)	TN2015000348A1 (en)
TW (1)	TWI636063B (en)
UA (1)	UA123198C2 (en)
WO (1)	WO2014137962A1 (en)
ZA (1)	ZA201505285B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR102417A1 (en) *	2014-11-05	2017-03-01	Lilly Co Eli	ANTI-TNF- / ANTI-IL-23 BIESPECTIFIC ANTIBODIES
CN108135983A (en) *	2015-10-30	2018-06-08	伊莱利利公司	Anti- CGRP/anti-il-23 bispecific antibody and application thereof
TW201902926A (en)	2017-05-03	2019-01-16	美商美國禮來大藥廠	anti-CGRP/anti-IL-23 bispecific antibody and use thereof
TWI744617B (en)	2018-03-30	2021-11-01	美商美國禮來大藥廠	Methods of treating ulcerative colitis
TWI808397B (en)	2018-09-11	2023-07-11	美商美國禮來大藥廠	Methods of treating psoriasis
TW202103734A (en)	2019-04-22	2021-02-01	美商美國禮來大藥廠	Methods of treating crohn’s disease
MX2022004311A (en)	2019-10-15	2022-05-10	Lilly Co Eli	Recombinantly engineered, lipase/esterase-deficient mammalian cell lines.
KR20220143005A (en)	2019-12-20	2022-10-24	노바록 바이오테라퓨틱스 리미티드	Anti-interleukin-23 P19 antibodies and methods of use thereof
CN112807428A (en) *	2020-06-12	2021-05-18	江苏荃信生物医药有限公司	Pharmaceutical composition comprising anti-human interleukin 23 monoclonal antibody
WO2022041390A1 (en) *	2020-08-28	2022-03-03	江苏荃信生物医药股份有限公司	Low viscosity liquid formulation comprising high concentration anti-human interleukin 23 monoclonal antibody, and preparation method therefor
TW202224702A (en)	2020-09-10	2022-07-01	美商美國禮來大藥廠	Therapeutic antibody formulations
CA3219846A1 (en)	2021-05-28	2022-12-01	Venkatesh Krishnan	Anti-il-23p19 antibody regulation of genes involved in ulcerative colitis
CN113698480B (en) *	2021-09-18	2022-07-01	东大生物技术(苏州)有限公司	Group of IL-23 monoclonal antibodies and medical application thereof
WO2023056417A1 (en)	2021-09-30	2023-04-06	Eli Lilly And Company	Anti-il-23p19 antibody regulation of genes involved in bowel urgency in ulcerative colitis
WO2024077113A1 (en)	2022-10-06	2024-04-11	Eli Lilly And Company	Methods of treating fatigue in ulcerative colitis

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6060284A (en)	1997-07-25	2000-05-09	Schering Corporation	DNA encoding interleukin-B30
US7090847B1 (en)	1999-09-09	2006-08-15	Schering Corporation	Mammalian cytokines; related reagents and methods
US7422743B2 (en)	2000-05-10	2008-09-09	Schering Corporation	Mammalian receptor protein DCRS5;methods of treatment
DK1601694T3 (en)	2003-03-10	2009-12-14	Schering Corp	Uses of IL23 antagonists, related reagents
US8003108B2 (en) *	2005-05-03	2011-08-23	Amgen Inc.	Sclerostin epitopes
TR201902033T4 (en) *	2005-06-30	2019-03-21	Janssen Biotech Inc	Anti-IL-23 antibodies, compositions, methods and uses.
EA013506B1 (en) *	2005-08-25	2010-06-30	Эли Лилли Энд Компани	Anti-il-23 antibodies
CN101248088A (en) *	2005-08-25	2008-08-20	伊莱利利公司	Anit-il-23 antibiodies
US7807160B2 (en)	2005-08-31	2010-10-05	Schering Corporation	Engineered anti-IL-23 antibodies
MX2008008621A (en) *	2005-12-29	2008-11-27	Centocor Inc	Human anti-il-23 antibodies, compositions, methods and uses.
EP2064242A1 (en) *	2007-02-23	2009-06-03	Schering Corporation	Engineered anti-il-23p19 antibodies
HUE042172T2 (en) *	2007-02-23	2019-06-28	Merck Sharp & Dohme	Engineered anti-il-23p19 antibodies
MY149129A (en) *	2007-03-20	2013-07-15	Lilly Co Eli	Anti-sclerostin antibodies
EP2144628B1 (en)	2007-05-08	2012-10-17	Genentech, Inc.	Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
WO2009082624A2 (en) *	2007-12-10	2009-07-02	Zymogenetics, Inc.	Antagonists of il-17a, il-17f, and il-23 and methods of using the same
EP2435480A1 (en) *	2009-05-27	2012-04-04	Ablynx N.V.	Biparatopic protein constructs directed against il-23
CA3017116A1 (en) *	2010-11-04	2012-05-10	Boehringer Ingelheim International Gmbh	Anti-il-23 antibodies
JP5987053B2 (en) *	2011-05-12	2016-09-06	ジェネンテック，インコーポレイテッド	Multiple reaction monitoring LC-MS / MS method for detecting therapeutic antibodies in animal samples using framework signature peptides

2014
- 2014-02-25 TW TW103106335A patent/TWI636063B/en active
- 2014-02-25 JO JOP/2014/0049A patent/JOP20140049B1/en active
- 2014-02-25 AR ARP140100582A patent/AR094877A1/en unknown
- 2014-03-04 EP EP20193400.7A patent/EP3789037A1/en not_active Withdrawn
- 2014-03-04 MX MX2015011959A patent/MX370396B/en active IP Right Grant
- 2014-03-04 CA CA2901462A patent/CA2901462C/en active Active
- 2014-03-04 EP EP23207282.7A patent/EP4311558A3/en active Pending
- 2014-03-04 CN CN201480012747.7A patent/CN105307681B/en active Active
- 2014-03-04 PT PT147610620T patent/PT2964258T/en unknown
- 2014-03-04 EA EA201591368A patent/EA031524B1/en not_active IP Right Cessation
- 2014-03-04 SG SG11201507176VA patent/SG11201507176VA/en unknown
- 2014-03-04 PE PE2015001903A patent/PE20151529A1/en active IP Right Grant
- 2014-03-04 LT LTEP14761062.0T patent/LT2964258T/en unknown
- 2014-03-04 DK DK14761062.0T patent/DK2964258T3/en active
- 2014-03-04 RS RS20201236A patent/RS60928B1/en unknown
- 2014-03-04 BR BR112015019611-0A patent/BR112015019611B1/en active IP Right Grant
- 2014-03-04 MA MA38382A patent/MA38382A1/en unknown
- 2014-03-04 KR KR1020177024414A patent/KR20170103037A/en not_active Application Discontinuation
- 2014-03-04 AP AP2015008708A patent/AP2015008708A0/en unknown
- 2014-03-04 US US14/195,889 patent/US9023358B2/en active Active
- 2014-03-04 ES ES14761062T patent/ES2822662T3/en active Active
- 2014-03-04 JP JP2015561515A patent/JP6096938B2/en active Active
- 2014-03-04 EP EP14761062.0A patent/EP2964258B1/en active Active
- 2014-03-04 HU HUE14761062A patent/HUE051357T2/en unknown
- 2014-03-04 KR KR1020157024032A patent/KR101775115B1/en active IP Right Grant
- 2014-03-04 SI SI201431653T patent/SI2964258T1/en unknown
- 2014-03-04 MY MYPI2015702927A patent/MY171226A/en unknown
- 2014-03-04 UA UAA201508670A patent/UA123198C2/en unknown
- 2014-03-04 WO PCT/US2014/020064 patent/WO2014137962A1/en active Application Filing
- 2014-03-04 AU AU2014226094A patent/AU2014226094B2/en active Active
- 2014-03-04 PL PL14761062T patent/PL2964258T3/en unknown
2015
- 2015-05-01 US US14/702,124 patent/US9688753B2/en active Active
- 2015-07-22 ZA ZA2015/05285A patent/ZA201505285B/en unknown
- 2015-08-12 TN TN2015000348A patent/TN2015000348A1/en unknown
- 2015-08-20 IL IL240731A patent/IL240731B/en active IP Right Grant
- 2015-08-26 CL CL2015002388A patent/CL2015002388A1/en unknown
- 2015-09-08 PH PH12015501994A patent/PH12015501994A1/en unknown
- 2015-09-08 EC ECIEPI201538626A patent/ECSP15038626A/en unknown
2016
- 2016-01-14 HK HK16100387.3A patent/HK1212252A1/en unknown
2017
- 2017-06-01 US US15/611,008 patent/US20170275356A1/en not_active Abandoned
2020
- 2020-01-14 IL IL272042A patent/IL272042B/en unknown
- 2020-10-09 HR HRP20201633TT patent/HRP20201633T1/en unknown
- 2020-11-16 CY CY20201101081T patent/CY1123589T1/en unknown
2023
- 2023-10-03 FI FIC20230030C patent/FIC20230030I1/en unknown
- 2023-10-06 NL NL301247C patent/NL301247I2/en unknown
- 2023-10-13 FR FR23C1036C patent/FR23C1036I1/en active Active
- 2023-10-18 HU HUS2300036C patent/HUS2300036I1/en unknown

Also Published As

Publication number	Publication date
NL301247I1 (en)	2023-10-11
EP2964258A4 (en)	2016-10-12
KR101775115B1 (en)	2017-09-05
US9023358B2 (en)	2015-05-05
HRP20201633T1 (en)	2020-12-25
US20140255422A1 (en)	2014-09-11
ES2822662T3 (en)	2021-05-04
CA2901462A1 (en)	2014-09-12
RS60928B1 (en)	2020-11-30
US20150232552A1 (en)	2015-08-20
IL272042B (en)	2021-07-29
BR112015019611B1 (en)	2023-05-02
JP2016510744A (en)	2016-04-11
HUE051357T2 (en)	2021-03-01
CN105307681A (en)	2016-02-03
KR20150113202A (en)	2015-10-07
PT2964258T (en)	2020-11-06
NL301247I2 (en)	2023-11-01
TN2015000348A1 (en)	2017-01-03
CL2015002388A1 (en)	2016-03-04
CN105307681B (en)	2018-06-26
UA123198C2 (en)	2021-03-03
TWI636063B (en)	2018-09-21
PL2964258T3 (en)	2021-02-08
EP4311558A2 (en)	2024-01-31
IL240731B (en)	2020-01-30
CY1123589T1 (en)	2022-03-24
LT2964258T (en)	2020-10-12
TW201520225A (en)	2015-06-01
SI2964258T1 (en)	2020-10-30
AU2014226094A1 (en)	2015-08-27
IL272042A (en)	2020-02-27
EP2964258A1 (en)	2016-01-13
MX370396B (en)	2019-12-11
MY171226A (en)	2019-10-03
EA031524B1 (en)	2019-01-31
HUS2300036I1 (en)	2023-11-28
EP3789037A1 (en)	2021-03-10
EA201591368A1 (en)	2015-12-30
FIC20230030I1 (en)	2023-10-03
DK2964258T3 (en)	2020-09-14
CA2901462C (en)	2017-07-25
AR094877A1 (en)	2015-09-02
WO2014137962A1 (en)	2014-09-12
AU2014226094B2 (en)	2016-06-23
NZ711147A (en)	2021-03-26
HK1212252A1 (en)	2016-06-10
SG11201507176VA (en)	2015-10-29
MX2015011959A (en)	2016-04-07
EP2964258B1 (en)	2020-09-02
MA38382A1 (en)	2017-11-30
ZA201505285B (en)	2017-11-29
US9688753B2 (en)	2017-06-27
PE20151529A1 (en)	2015-10-28
ECSP15038626A (en)	2015-11-30
US20170275356A1 (en)	2017-09-28
KR20170103037A (en)	2017-09-12
IL240731A0 (en)	2015-10-29
BR112015019611A2 (en)	2017-08-22
PH12015501994A1 (en)	2016-01-11
EP4311558A3 (en)	2024-04-10
JP6096938B2 (en)	2017-03-15
JOP20140049B1 (en)	2021-08-17
AP2015008708A0 (en)	2015-09-30

Publication	Publication Date	Title
FR23C1036I1 (en)	2023-12-08	ANTIBODIES THAT BIND TO IL-23
NO2021007I1 (en)	2021-02-19	calcifediol
DK3049441T3 (en)	2020-02-03	Anti-PDL1 antibody formulations
KR102355950B9 (en)	2023-10-26	Antibodies to TIGIT
MA45004A (en)	2019-03-27	ANTI-WT1-HLA SPECIFIC ANTIBODIES
DK3336106T3 (en)	2020-07-13	ANTI-FCRH5 ANTIBODIES
MA47472A (en)	2019-12-18	ANTIBODY
DK3708583T3 (en)	2022-05-16	NON-FUCOSYLED ANTI-FGFR2IIIB ANTIBODIES
DK2970460T3 (en)	2020-06-02	Anti-IL-33 Antibodies and Uses thereof
FR3014362B1 (en)	2017-03-17	PERFECTIONED ROLLING ASSEMBLY
DK3053119T3 (en)	2020-02-17	PAPERLESS USE
MA42843A (en)	2018-07-25	ANTI-CD115 ANTIBODY
DK3003386T3 (en)	2020-01-27	ANTIBODY DRUG CONJUGATES
CL2016001147A1 (en)	2017-02-17	Specific antibodies to fcrn.
DK3047188T3 (en)	2021-08-23	PIPE CONNECTION
DK3065774T3 (en)	2021-08-23	Anti-CCL17 antibodies
FR3002228B1 (en)	2016-02-19	MONOCLONAL ANTIBODIES AND USES
FI20130201A (en)	2015-01-06	Serum cholesterol-lowering composition
FI20135464A (en)	2014-11-04	Pipe
TH1401006962A (en)	2016-06-17	Anti-transglutaminase 2 antibody
FR3004184B1 (en)	2016-03-18	ANTI-GLUTEN ANTIBODY DESAMIDE AND USES THEREOF.
TH1401007591A (en)	2016-09-06	Immunoconjugate containing anti-CD79B antibody
TH1401007915B (en)	2016-03-21	Friction materail
TH1401005842A (en)	2016-11-09	Antibodies to CDR-modified SIGLEC-15
ITMC20130025U1 (en)	2015-04-09	PROPORTIONAL FLAT PEDAL PEDAL